Home>>Signaling Pathways>> Others>>NE 10790 (3-PEHPC)

NE 10790 (3-PEHPC) (Synonyms: 3-PEHPC)

Catalog No.GC30592

NE 10790 (3-PEHPC), a poor farnesyl pyrophosphate synthase inhibitor, is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent.

Products are for research use only. Not for human use. We do not sell to patients.

NE 10790 (3-PEHPC) Chemical Structure

Cas No.: 152831-36-2

Size Price Stock Qty
10mM (in 1mL Water)
$277.00
In stock
5mg
$252.00
In stock
10mg
$405.00
In stock
50mg
$1,215.00
In stock
100mg
$1,951.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NE 10790, a poor farnesyl pyrophosphate synthase inhibitor, is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent.

NE 10790 inhibits incorporation of [14C]mevalonic acid into Rab6, but not into H-Ras or Rap1, proteins that are modified by FTase and GGTase I, respectively. NE 10790 reduces viability in J774 cells. NE 10790 prevents prenylation of 22-26-kDa proteins that are not modified by FTase or GGTase I[1].

[1]. Coxon FP, et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem. 2001 Dec 21;276(51):48213-22.

Reviews

Review for NE 10790 (3-PEHPC)

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NE 10790 (3-PEHPC)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.